Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O9ES
|
||||
| Former ID |
DIB019154
|
||||
| Drug Name |
cloprostenol
|
||||
| Synonyms |
ICI 80996
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H29ClO6
|
||||
| InChI |
InChI=1S/C22H29ClO6/c23-15-6-5-7-17(12-15)29-14-16(24)10-11-19-18(20(25)13-21(19)26)8-3-1-2-4-9-22(27)28/h1,3,5-7,10-12,16,18-21,24-26H,2,4,8-9,13-14H2,(H,27,28)/b3-1-,11-10+/t16-,18-,19-,20+,21-/m1/s1
|
||||
| InChIKey |
VJGGHXVGBSZVMZ-QIZQQNKQSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7978976, 11056237, 14880541, 26754922, 26754923, 39340782, 47216548, 48110216, 50110831, 53787345, 76608563, 85787684, 92309995, 99300907, 103214324, 103985320, 114155154, 126618228, 126662417, 135260747, 135650113, 143086659, 152104394, 162175052, 162200047, 162259055, 163475429, 163640402, 175270114, 198961784, 223673329, 226494655, 241077811, 252455719, 252457292
|
||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin E2 receptor, EP1 subtype | Target Info | Agonist | [2] | |
| Prostaglandin F2-alpha receptor | Target Info | Agonist | [3] | ||
| Prostaglandin E2 receptor EP3 subtype | Target Info | Agonist | [3] | ||
| Thromboxane A2 receptor | Target Info | Agonist | [3] | ||
| Prostaglandin D2 receptor | Target Info | Agonist | [3] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Pathways in cancerhsa04020:Calcium signaling pathway | |||||
| Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway | |||||
| cAMP signaling pathway | |||||
| Regulation of lipolysis in adipocytes | |||||
| Platelet activationhsa04080:Neuroactive ligand-receptor interaction | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | PI3 kinase pathway | ||||
| Pathway Interaction Database | Thromboxane A2 receptor signaling | ||||
| PathWhiz Pathway | Intracellular Signalling Through PGD2 receptor and Prostaglandin D2 | ||||
| Reactome | Prostanoid ligand receptors | ||||
| G alpha (q) signalling eventsR-HSA-391908:Prostanoid ligand receptors | |||||
| G alpha (i) signalling eventsR-HSA-391908:Prostanoid ligand receptors | |||||
| G alpha (q) signalling events | |||||
| G alpha (12/13) signalling events | |||||
| Thromboxane signalling through TP receptorR-HSA-391908:Prostanoid ligand receptors | |||||
| G alpha (s) signalling events | |||||
| WikiPathways | Prostaglandin Synthesis and Regulation | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Small Ligand GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP98:Prostaglandin Synthesis and Regulation | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP98:Prostaglandin Synthesis and Regulation | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| Signal amplification | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1894). | ||||
| REF 2 | Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47. | ||||
| REF 3 | The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.